SEC Filing Summary: Synta Pharmaceuticals Corp.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on January 11, 2012. The report addresses the closing of a previously announced public offering of common stock. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses solely on the equity transaction details.
- Transaction Type: Public offering of common stock.
- Shares Issued: 7,000,000 shares.
- Transaction Status: Closed as of January 11, 2012.
Material Changes
The primary material change reported is the increase in outstanding common stock resulting from the closing of the 7,000,000 share offering. No comparative financial data or prior period metrics are included in this specific filing.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the equity offering. The press release detailing the offering is incorporated by reference as Exhibit 99.1 but is not included in the provided text.
Investor Verification Checklist
- Verify the offering price per share and total gross proceeds in the press release (Exhibit 99.1).
- Confirm the updated total number of outstanding shares post-offering.
- Review the use of proceeds disclosed in the accompanying press release.
- Check for any underwriting agreements or lock-up provisions referenced in the full press release.